Yong Teng, PhD, is a professor in the Department of Hematology and Medical Oncology at Emory University School of Medicine, Atlanta, Georgia. Dr. Teng is a Winship Cancer Institute member engaged in basic cancer research and translational medicine. Prior to joining Emory in 2021, he was a tenured associate professor of the Department of Oral Biology and Dx Sciences and Georgia Cancer Center member at Augusta University.
Dr. Teng is a member of the Cell and Molecular Biology Research Program at Winship Cancer Institute of Emory University.
Education
Dr. Teng earned his PhD in molecular biology at Sun Yat-sen University in Guangzhou, China. He received his postdoctoral training in cancer biology and genetics at Medical College of Georgia in Augusta, Georgia.
Titles & Roles
Professor, Department of Hematology and Medical Oncology
Emory University School of Medicine
Professional Memberships
Dr. Teng is an active member of American Association for Cancer Research and Royal Society of Medicine. He is a fellow of the International Association of Advanced Materials, VEBLEO and the Royal Society of Medicine, and was appointed as USA Bentham Ambassador.
Research
Dr. Teng's research interests lie primarily in bridging three major themes, the tumor microenvironment, tumor metabolism and metastasis while placing a special emphasis on several molecular determinants such as FGF19/FGFR4, ATAD3A, Arf1 and WASF3, and translating these scientific discoveries into better cancer treatments.
Dr. Teng uses head and neck cancer cell lines and preclinical animal models as the main research platform to gain critical insights in three major areas of research:
Understand and reverse mechanisms of cancer metabolism, metastasis, and immune evasion.
Decipher mechanistic basis underlying treatment resistance in tumors with specific genetic backgrounds.
Develop novel anticancer strategies such as tumor-seeking nanomedicines, therapeutic stapled peptides, and oncolytic viruses) and more effective therapies that can simultaneously elicit tumor regression and prime antitumor immunity.
Dr. Teng and his team have authored over 100 articles and book chapters relating to the mechanistic understanding of cancer and treatment responses. He is a topic editor for many special issues and research topics and serves as reviewer for numerous upper-tier journals.
Dr. Teng is the associate editor-in-chief or editorial board member for several reputed journals including the Journal of Experimental and Clinical Cancer Research, Frontiers in Oncology, and Frontiers in Molecular Biosciences. He also serves on several national and international grant review panels.
